Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Cash from Investing Activities (2021 - 2025)

Historic Cash from Investing Activities for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $47.7 million.

  • Aligos Therapeutics' Cash from Investing Activities rose 35857.86% to $47.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.8 million, marking a year-over-year increase of 5861.52%. This contributed to the annual value of -$18.3 million for FY2024, which is 14063.72% down from last year.
  • Aligos Therapeutics' Cash from Investing Activities amounted to $47.7 million in Q3 2025, which was up 35857.86% from -$39.4 million recorded in Q2 2025.
  • Over the past 5 years, Aligos Therapeutics' Cash from Investing Activities peaked at $47.7 million during Q3 2025, and registered a low of -$88.6 million during Q1 2024.
  • In the last 5 years, Aligos Therapeutics' Cash from Investing Activities had a median value of $9.7 million in 2021 and averaged -$1.7 million.
  • In the last 5 years, Aligos Therapeutics' Cash from Investing Activities crashed by 72317.14% in 2022 and then surged by 28541428.57% in 2024.
  • Quarter analysis of 5 years shows Aligos Therapeutics' Cash from Investing Activities stood at -$16.5 million in 2021, then skyrocketed by 170.42% to $11.6 million in 2022, then plummeted by 100.06% to -$7000.0 in 2023, then surged by 285414.29% to $20.0 million in 2024, then surged by 138.75% to $47.7 million in 2025.
  • Its last three reported values are $47.7 million in Q3 2025, -$39.4 million for Q2 2025, and -$44.1 million during Q1 2025.